Kraig Biocraft Laboratories (KBLB) Debt to Equity (2018 - 2022)
Kraig Biocraft Laboratories (KBLB) has disclosed Debt to Equity for 7 consecutive years, with -$0.03 as the latest value for Q3 2022.
- Quarterly Debt to Equity fell 0.95% to -$0.03 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$0.03 through Sep 2022, down 0.95% year-over-year, with the annual reading at -$0.03 for FY2021, N/A changed from the prior year.
- Debt to Equity hit -$0.03 in Q3 2022 for Kraig Biocraft Laboratories, up from -$0.03 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$0.03 in Q1 2021 to a low of -$0.82 in Q4 2018.
- Historically, Debt to Equity has averaged -$0.11 across 4 years, with a median of -$0.03 in 2022.
- Biggest YoY gain for Debt to Equity was 7.68% in 2022; the steepest drop was 16.14% in 2022.
- Year by year, Debt to Equity stood at -$0.82 in 2018, then soared by 93.22% to -$0.06 in 2019, then skyrocketed by 47.52% to -$0.03 in 2021, then rose by 0.67% to -$0.03 in 2022.
- Business Quant data shows Debt to Equity for KBLB at -$0.03 in Q3 2022, -$0.03 in Q2 2022, and -$0.03 in Q1 2022.